New Two-Drug combo aims to shrink tumors before surgery
NCT ID NCT06279130
Summary
This study is testing whether giving two immunotherapy drugs (botensilimab and balstilimab) before surgery can help shrink tumors in patients with various types of solid cancers. The goal is to see if this approach leads to less cancer remaining after surgery and better long-term outcomes. The trial is enrolling 133 adults with operable tumors who have not had prior cancer treatments like chemotherapy or immunotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE MMR-DEFICIENT SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Netherlands Cancer Institute
RECRUITINGAmsterdam, North Holland, 1066 CX, Netherlands
Contact
Contact
Conditions
Explore the condition pages connected to this study.